OR WAIT null SECS
CAGR growth through 2026 will be 6.4% per year
Following the tumult of the 2020 pandemic—now leaking well into 2021—the market research firm Evaluate Pharma projects a healthy growth for the current year, based on data collected during the first half of 2021. It remains to be seen whether the renewed infection rates, spurred by the Delta variant of the Covid-19 virus, will suppress that projected 2021 growth.
Evaluate Pharma’s report, World Preview 2021 Outlook to 2026, presents high-level summaries of data the Evaluate Pharma produces and publishes during the year. Among other highlights: